A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection

• Published in: Journal of the American Society of Nephrology Vol. 32; no. 3; pp. 708 - 722
• Main Authors: Doberer, Konstantin, Duerr, Michael, Halloran, Philip F., Eskandary, Farsad, Budde, Klemens, Regele, Heinz, Reeve, Jeff, Borski, Anita, Kozakowski, Nicolas, Reindl-Schwaighofer, Roman, Waiser, Johannes, Lachmann, Nils, Schranz, Sabine, Firbas, Christa, Mühlbacher, Jakob, Gelbenegger, Georg, Perkmann, Thomas, Wahrmann, Markus, Kainz, Alexander, Ristl, Robin, Halleck, Fabian, Bond, Gregor, Chong, Edward, Jilma, Bernd, Böhmig, Georg A.
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.03.2021
• Subjects: Adult; Allografts; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Clinical Research; Double-Blind Method; Female; Glomerular Filtration Rate; Graft Rejection - immunology; Graft Rejection - physiopathology; Graft Rejection - therapy; Humans; Infections - etiology; Interleukin-6 - antagonists & inhibitors; Interleukin-6 - immunology; Isoantibodies - blood; Kidney Transplantation - adverse effects; Male; Middle Aged; Tissue Donors; Treatment Outcome; Young Adult; chronic rejection; monoclonal antibody; renal transplantation; interleukin-6; antibody-mediated rejection; randomized controlled trial
• ISSN: 1046-6673; 1533-3450; 1533-3450
• DOI: 10.1681/ASN.2020071106

Late antibody-mediated rejection (ABMR) is a leading cause of transplant failure. Blocking IL-6 has been proposed as a promising therapeutic strategy. We performed a phase 2 randomized pilot trial to evaluate the safety (primary endpoint) and efficacy (secondary endpoint analysis) of the anti-IL-6 antibody clazakizumab in late ABMR. The trial included 20 kidney transplant recipients with donor-specific, antibody-positive ABMR ≥365 days post-transplantation. Patients were randomized 1:1 to receive 25 mg clazakizumab or placebo (4-weekly subcutaneous injections) for 12 weeks (part A), followed by a 40-week open-label extension (part B), during which time all participants received clazakizumab. Five (25%) patients under active treatment developed serious infectious events, and two (10%) developed diverticular disease complications, leading to trial withdrawal. Those receiving clazakizumab displayed significantly decreased donor-specific antibodies and, on prolonged treatment, modulated rejection-related gene-expression patterns. In 18 patients, allograft biopsies after 51 weeks revealed a negative molecular ABMR score in seven (38.9%), disappearance of capillary C4d deposits in five (27.8%), and resolution of morphologic ABMR activity in four (22.2%). Although proteinuria remained stable, the mean eGFR decline during part A was slower with clazakizumab compared with placebo (-0.96; 95% confidence interval [95% CI], -1.96 to 0.03 versus -2.43; 95% CI, -3.40 to -1.46 ml/min per 1.73 m per month, respectively, =0.04). During part B, the slope of eGFR decline for patients who were switched from placebo to clazakizumab improved and no longer differed significantly from patients initially allocated to clazakizumab. Although safety data indicate the need for careful patient selection and monitoring, our preliminary efficacy results suggest a potentially beneficial effect of clazakizumab on ABMR activity and progression.